Novo Nordisk (NVO) shares showed little change after the company reported new trial data for its oral diabetes drug. The stock trades near $39 and is down about 21% so far this year, with no clear move tied to the update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company said its oral GLP-1 drug helped lower blood sugar levels in children and teens with type 2 diabetes. The late-stage trial met its main goal, marking a key step as Novo looks to expand the use of its top drugs.
Despite the positive data, the stock did not move much. This suggests that investors may already expect growth from GLP-1 drugs, or they may be waiting for approval and sales data.
Trial Results Point to New Growth Path
In the study, Novo tested the pill in 132 patients aged 10 to 17 over 26 weeks. The results showed a 0.83% drop in blood sugar compared with the placebo. The firm said the result was “statistically significant,” which supports a path to approval.
This is the first time an oral GLP-1 drug has shown success in this age group. Today, most young patients rely on metformin or insulin. However, metformin fails in about half of cases, while insulin can lead to weight gain and low blood sugar.
As a result, Novo may be able to fill a gap in care. The firm plans to file for approval in the U.S. and Europe in the second half of 2026. If cleared, the drug could become the first oral GLP 1 option for children.
At the same time, this move could expand the reach of semaglutide, the key drug behind Ozempic and Rybelsus. It may also allow Novo to reach patients earlier in life, which can support long-term demand.
Novo Nordisk Drug Pipeline
Rival Pressure and Market Competition
At the same time, the update has clear meaning for Eli Lilly (LLY), Novo’s main rival in diabetes and weight-loss care. Lilly leads with strong injectable drugs, while Novo has built an edge in oral forms.
With this new data, Novo may gain an early lead in the pediatric space, where no oral GLP-1 drugs are yet approved. This could help it lock in young patients before Lilly brings a rival option to market.
However, the broader race remains close. Both firms continue to invest in next-wave drugs, and each aims to expand into new groups of patients. As a result, while this trial supports Novo’s position, it does not shift the balance on its own.
Is NVO a Good Stock to Buy?
Turning to the Street, Novo Nordisk boasts a Hold consensus, based on eight analysts’ ratings. The average NVO stock price target is $43, implying a 9.83% upside from the current price.
